Clinical Trials Logo

Chronic Inflammatory Rheumatism clinical trials

View clinical trials related to Chronic Inflammatory Rheumatism.

Filter by:
  • None
  • Page 1

NCT ID: NCT05026892 Not yet recruiting - Autoimmune Diseases Clinical Trials

Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases

CovAID
Start date: August 2021
Phase:
Study type: Observational

Factors associated with severe forms of COVID-19 infection in patients with inflammatory rheumatic diseases (IRD) or Autoimmune Diseases (AID) are unknown. This unprecedented situation leads to empirical and potentially erroneous advice and recommendations for care. Identifying factors associated with severity, in the context of this pandemic, which is expected to last many months, and possibly years, is crucial for future patients. The objective of this work is to identify the factors associated with the occurrence of severe forms of COVID-19 infection in patients with IRD or AID, by combining analysis of 2 large databases.

NCT ID: NCT04749875 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Study of Leukocyte Populations in Patients With Chronic Inflammatory

LIMA
Start date: March 1, 2021
Phase:
Study type: Observational

Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.

NCT ID: NCT04530682 Completed - Clinical trials for Chronic Inflammatory Rheumatism

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

COVIDRIC-2
Start date: March 5, 2021
Phase:
Study type: Observational

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

NCT ID: NCT04353609 Recruiting - Autoimmune Diseases Clinical Trials

Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases

covid19 fai2r
Start date: April 18, 2020
Phase:
Study type: Observational

Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

NCT ID: NCT04174092 Completed - Clinical trials for Chronic Inflammatory Rheumatism

Catastrophism in Chronic Inflammatory Rheumatism

CRIC
Start date: October 27, 2019
Phase: N/A
Study type: Interventional

Catastrophic is defined as a negative cognitive and emotional response based on inadequate pain expression. It has three components: rumination, amplification and vulnerability. The assessment of catastrophism is carried out using a validated questionnaire called the "Pain Catatrophizing Scale" (PCS). Recent studies highlight the significant impact of catastrophism in neuromuscular and mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these diseases, it has been shown that catastrophism has a negative impact both on the experience of pain and on the response to different types of treatments (medical and surgical). Several studies have implemented multidisciplinary management and in particular cognitive-behavioural therapy with an improvement in the pain experience in patients who are catastrophic. In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly understood.